ASCO 2026: Latest updates in mRCC
Dr Ana Arance speaks to ecancer at ESMO 2019 in Barcelona about the IMspire170 trial for advanced melanoma.
She explains the study design and how the study did not reach the primary endpoint.
Dr Arance outlines some of the reasons why this could be the case, and what areas need to be looked at in more detail.
ASCO 2026: Latest updates in mRCC
ASCO GU 2026: Updates in metastatic prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ASCO 2024: Lung cancer highlights